Drug Trial Radar · NCT07764692
A Phase I Clinical Trial to Evaluate the Effect of Itraconazole on the Pharmacokinetics of HS-10504
Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
8
Planned (sponsor's estimate)
Start
Aug 1, 2026
Primary completion
Mar 1, 2027
Study completion Mar 31, 2027
Sponsor
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single-center, open-label, fixed-sequence, self-controlled Phase I clinical study with a planned enrollment of approximately 18 healthy participants.
Conditions
- Healthy Participants
Interventions
HS-10504Drug
Participants will receive a single oral dose of 400 mg HS-10504 tablets on study days D1 and D15, respectively。
Itraconazole CapsulesDrug
Participants will receive itraconazole capsules 0.2 g orally once daily from Day 11 to Day 23 for 13 consecutive days (with co-administration of itraconazole and HS-10504 on an empty stomach on Day 15)。
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluation of PK parameters of HS-10504 and M6-2: CmaxTime frame: 216 hours after administration of HS-10504
- Evaluation of PK parameters of HS-10504 and M6-2: AUC0-tTime frame: 216 hours after administration of HS-10504
- Evaluation of PK parameters of HS-10504 and M6-2:AUC0-∞Time frame: 216 hours after administration of HS-10504
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.